Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Genmab A/S - American Depositary Shares (NQ:GMAB)

31.58 -0.94 (-2.89%)
Streaming Delayed Price Updated: 3:48 PM EST, Dec 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,186,236
Open 31.98
Bid (Size) 31.58 (200)
Ask (Size) 31.59 (400)
Prev. Close 32.52
Today's Range 31.39 - 32.00
52wk Range 17.23 - 33.96
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Genmab Stock Slips After Discontinuing Further Development Of Cancer Drug Developed With BioNTech ↗
The company has decided to concentrate on cancer therapies Epkinly, Petosemtamab and Rina‑S, which are in late-stage development. 
Via Stocktwits
Topics Supply Chain
News headline image
Biopharma’s Year-End Rollercoaster: Mereo Plummets 90% as BioMarin Seals $4.8 Billion Amicus Deal
The biopharmaceutical sector witnessed a dramatic surge in volatility today, December 29, 2025, as the industry careened toward the end of its strongest year in two decades. In a day defined by extreme... 
Via MarketMinute
Topics ETFs Intellectual Property

Performance

YTD
+50.4%
+50.4%
1 Month
+0.6%
+0.6%
3 Month
+7.7%
+7.7%
6 Month
+52.9%
+52.9%
1 Year
+52.1%
+52.1%

More News

Read More
News headline image
Genmab Portfolio Prioritization Update
From Genmab A/S
Via Business Wire
News headline image
Genmab Announces Completion of Tender Offer for Outstanding Common Shares of Merus N.V. and Commencement of Subsequent Offering Period
From Genmab A/S
Via Business Wire
News headline image
Genmab Announces New Data from Phase 1b/2 EPCORE® CLL-1 Highlighting Potential of Epcoritamab as Monotherapy and in Combination for Patients with Richter Transformation (RT)
From Genmab A/S
Via Business Wire
News headline image
Genmab Presents Pivotal Phase 3 Data from EPCORE® FL-1 Trial Demonstrating Clinical Benefit of EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide (R2) in Patients with Relapsed or Refractory Follicular Lymphoma
From Genmab A/S
Via Business Wire
News headline image
Genmab Announces Data From Multiple Clinical Trials Showing Treatment with Fixed-Duration Epcoritamab Led to Remissions in First-Line Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL)
From Genmab A/S
Via Business Wire
News headline image
Genmab (GMAB) Q3 2025 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
News headline image
Major Victory For Genmab As Epkinly Receives FDA Approval For Type Of Pretreated Blood Cancer ↗
Via Benzinga
News headline image
Genmab Announces EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide Approved by the U.S. Food and Drug Administration for the Treatment of Relapsed or Refractory Follicular Lymphoma
From Genmab A/S
Via Business Wire
News headline image
Halozyme Stock Surging On Recent Earnings Beat; Record High Ahead? ↗
Via Investor's Business Daily
News headline image
Zscaler To Rally More Than 9%? Here Are 10 Top Analyst Forecasts For Monday ↗
Via Benzinga
News headline image
Genmab to Showcase Latest Blood Cancer Treatment Advancements at 2025 American Society of Hematology (ASH) Annual Meeting
From Genmab A/S
Via Business Wire
News headline image
Why Is Genmab Stock Trading Lower On Monday? ↗
Via Benzinga
News headline image
Olema Pharmaceuticals, Exelixis, Genmab And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗
Via Benzinga
News headline image
Genmab Announces New Data Demonstrating Investigational Rinatabart Sesutecan (Rina-S®) Achieved Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer
From Genmab
Via Business Wire
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Electronic Arts Inc. (Nasdaq - EA), Merus N.V. (Nasdaq – MRUS), Berry Corporation (Nasdaq - BRY), Semler Scientific, Inc. (Nasdaq – SMLR)
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
Why Genmab Stock Popped on Friday ↗
Via The Motley Fool
News headline image
Curious about the stocks that are showing activity after the closing bell on Friday? ↗
Via Chartmill
News headline image
Why Genmab Stock Was Marching Higher Today ↗
Via The Motley Fool
News headline image
Merus N.V. Soars on $8 Billion Genmab Acquisition, Propelled by Oncology Pipeline Successes
Via MarketMinute
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Electronic Arts Inc. (Nasdaq – EA), Merus N.V. (Nasdaq – MRUS), Berry Corporation (Nasdaq – BRY), Semler Scientific, Inc. (Nasdaq – SMLR)
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
Genmab Makes $8 Billion Bet On Merus With Potential Cancer Breakthrough ↗
Via Benzinga
News headline image
Genmab Strikes $8 Billion Deal To Acquire Cancer-Focused Merus ↗
Via Investor's Business Daily
Topics Government
News headline image
Genmab to Acquire Merus, Expanding Late-Stage Pipeline and Accelerating into a Wholly Owned Model
From Genmab A/S
Via Business Wire

Frequently Asked Questions

Is Genmab A/S - American Depositary Shares publicly traded?
Yes, Genmab A/S - American Depositary Shares is publicly traded.
What exchange does Genmab A/S - American Depositary Shares trade on?
Genmab A/S - American Depositary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for Genmab A/S - American Depositary Shares?
The ticker symbol for Genmab A/S - American Depositary Shares is GMAB on the Nasdaq Stock Market
What is the current price of Genmab A/S - American Depositary Shares?
The current price of Genmab A/S - American Depositary Shares is 31.58
When was Genmab A/S - American Depositary Shares last traded?
The last trade of Genmab A/S - American Depositary Shares was at 12/30/25 03:48 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.